Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

被引：0
|
作者：
Bibian M. E. Tullemans
Sanne L. N. Brouns
Frauke Swieringa
Siamack Sabrkhany
Franchette W. P. J. van den Berkmortel
Natascha A. J. B. Peters
Peter de Bruijn
Stijn L. W. Koolen
Johan W. M. Heemskerk
Maureen J. B. Aarts
Marijke J. E. Kuijpers
机构：
[1] Maastricht University,Cardiovascular Research Institute Maastricht, Department of Biochemistry
[2] Synapse Research Institute,Cardiovascular Research Institute Maastricht, Department of Physiology
[3] Maastricht University,Department of Medical Oncology
[4] Zuyderland Medical Centre,Department of Internal Medicine
[5] Sint Jans Gasthuis,Department of Medical Oncology, Erasmus MC Cancer Institute
[6] Erasmus University Medical Centre,Thrombosis Expertise Centre, Heart and Vascular Centre
[7] Department of Pharmacy,undefined
[8] Erasmus University Medical Centre,undefined
[9] Department of Medical Oncology,undefined
[10] Maastricht University Medical Centre+,undefined
[11] Maastricht University Medical Centre,undefined
来源：
BMC Cancer | / 22卷
关键词：
Platelet count; Platelet aggregation; Sunitinib; Tyrosine kinase inhibitor; Renal cell carcinoma; cancer; Patients; Plasma; Serum; Bleeding;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 41 条
  • [31] Prognostic Significance of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma Treated With First-Line Sunitinib: A European Multiinstitutional Study
    Bamias, Aristotle
    Tzannis, Kimon
    Papatsoris, Athanasios
    Oudard, Stephane
    Beuselinck, Benoit
    Escudier, Bernard
    Liontos, Michalis
    Elaidi, Thierry-Reja
    Chrisofos, Michael
    Stravodimos, Konstantinos
    Anastasiou, Ioannis
    Mitropoulos, Dionisios
    Deliveliotis, Charalambos
    Constantinides, Constantinos
    Dimopoulos, Meletios-Athanasios
    Bamia, Christina
    CLINICAL GENITOURINARY CANCER, 2014, 12 (05) : 373 - 383
  • [32] Prognostic significance of nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC) treated with 1st line sunitinib: A European collaborative study
    Bamias, A.
    Tzannis, K.
    Oudard, S.
    Beuselinck, B.
    Escudier, B.
    Elaidi, R.
    Chrisofos, M.
    Papatsoris, A.
    Dimopoulos, M. A.
    Bamia, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S641 - S641
  • [33] Contrast enhanced CT (CE-CT) changes and nephrometry down-scoring of unresectable primary renal cell carcinoma (RCC) tumors in patients (Pts) treated with neoadjuvant sunitinib
    Salem, M.
    Shah, S. N.
    Wood, L. S.
    Elson, P.
    Medsinge, A.
    Campbell, S.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [34] Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
    Garcia-Donas, Jesus
    Esteban, Emilio
    Javier Leandro-Garcia, Luis
    Castellano, Daniel E.
    Gonzalez del Alba, Aranzazu
    Angel Climent, Miguel
    Angel Arranz, Jose
    Gallardo, Enrique
    Puente, Javier
    Bellmunt, Joaquim
    Mellado, Begona
    Martinez, Esther
    Moreno, Fernando
    Font, Albert
    Robledo, Mercedes
    Rodriguez-Antona, Cristina
    LANCET ONCOLOGY, 2011, 12 (12): : 1143 - 1150
  • [35] Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study
    Kucharz, Jakub
    Dumnicka, Paulina
    Kuzniewski, Marek
    Kusnierz-Cabala, Beata
    Herman, Roman Maria
    Krzemieniecki, Krzysztof
    TUMORI JOURNAL, 2015, 101 (05): : 555 - 559
  • [36] Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib.
    Rodriguez-Moreno, Jf.
    Esteban, Emilio
    Javier Leandro-Garcia, Luis
    Castellano, Daniel E.
    Gonzalez del Alba, Aranzazu
    Angel Climent, Miguel
    Angel Arranz, Jose
    Gallardo, Enrique
    Puente, Javier
    Bellmunt, Joaquim
    Mellado, Begona
    Martinez, Esther
    Moreno, Fernando
    Font, Albert
    Robledo, Mercedes
    Hernando Polo, Susana
    Garcia-Donas, Jesus
    Rodriguez-Antona, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [37] The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: A Japanese retrospective study Urology
    Miyake M.
    Kuwada M.
    Hori S.
    Morizawa Y.
    Tatsumi Y.
    Anai S.
    Hosokawa Y.
    Hayashi Y.
    Tomioka A.
    Otani T.
    Otsuka K.
    Nakagawa Y.
    Nakai Y.
    Samma S.
    Tanaka N.
    Fujimoto K.
    BMC Research Notes, 9 (1)
  • [38] Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR) a randomised, phase 3 study
    Motzer, Robert
    Porta, Camillo
    Alekseev, Boris
    Rha, Sun Young
    Choueiri, Toni K.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Goh, Jeffrey C.
    Eto, Masatoshi
    Bennett, Lee
    Wang, Jinyi
    Pan, Jie Janice
    Saretsky, Todd L.
    Perini, Rodolfo F.
    He, Cixin Steven
    Mody, Kalgi
    Cella, David
    LANCET ONCOLOGY, 2022, 23 (06): : 768 - 780
  • [39] Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomized, phase 3 study
    Motzer, R.
    Porta, C.
    Alekseev, B.
    Rha, S. Y.
    Choueiri, T. K.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Kapoor, A.
    Goh, J. C.
    Eto, M.
    Bennett, L.
    Wang, J.
    Pan, J. J.
    Saretsky, T. L.
    Perini, R. F.
    He, C. S.
    Mody, K.
    Cella, D.
    ONKOUROLOGIYA, 2022, 18 (02): : 39 - 57
  • [40] Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?
    Basaran, Mert
    Yildiz, Ibrahim
    Sen, Fatma
    Kilic, Leyla
    Keskin, Serkan
    Darendeliler, Emin
    Bavbek, Sevil E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345